Ark Invest, through its ARK Fintech Innovation ETF ARKF -5.46% + Free Alerts , bought 162,143 shares of Nu Holdings Ltd. This marks a significant investment in the fintech company, reflecting Ark’s ...
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
EST Cathie Wood’s ARK Investment buys 171K shares of Beam Therapeutics (BEAM) todayDiscover the Best Stocks and Maximize Your Portfolio: ...
Has Beam Therapeutics Inc. (BEAM) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that ...
NASDAQ BEAM opened at $25.59 on Monday. Beam Therapeutics has a 52 week low of $20.84 and a 52 week high of $49.50. The business’s fifty day simple moving average is $26.50 and its 200-day ...
NASDAQ BEAM opened at $28.57 on Thursday. The firm has a market cap of $2.37 billion, a PE ratio of -16.23 and a beta of 1.92. Beam Therapeutics has a 1-year low of $20.84 and a 1-year high of $49 ...
2025年2月20日， Beam Therapeutics（BEAM）披露1笔公司内部人交易情况。高管Cavanagh Bethany J于2025年2月18日卖出6287股。 2025年2月20日 高管 Cavanagh Bethany J 2025年2月18日 卖出 6287 35.00 22.00万 2025年2月19日 高管 Bellon Christine 2025年2月14日 卖出 1 ...
Cathie Wood的ARK ETF基金公布了2025年2月20日星期四的每日交易数据，显示其继续专注于基因组创新领域，并对其科技和机器人投资组合进行调整。引起投资者关注的是，ARK通过其ARKK和ARKG基金大幅增持了Beam Therapeutics Inc（NASDAQ:BEAM）的持股，总计购入170,778股，价值约$5.82million。
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback